FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types.
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H.
Zhang X, et al. Among authors: deng x.
Mol Ther Oncol. 2024 Oct 18;32(4):200895. doi: 10.1016/j.omton.2024.200895. eCollection 2024 Dec 19.
Mol Ther Oncol. 2024.
PMID: 39583007
Free PMC article.